Skip to main navigation
Skip to search
Skip to main content
Research Profiles at Washington University School of Medicine Home
Help & FAQ
Home
Profiles
Departments, Divisions and Centers
Research output
Search by expertise, name or affiliation
Prognosis and risk stratification of peripheral T-cell lymphomas
Mary Kate Malecek,
Neha Mehta-Shah
Section of Medical Oncology
Institute of Clinical and Translational Sciences (ICTS)
Siteman Cancer Center
Research output
:
Contribution to journal
›
Article
›
peer-review
4
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Prognosis and risk stratification of peripheral T-cell lymphomas'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Active Area
33%
B-cell Lymphoma
33%
Brentuximab Vedotin
33%
CD30
33%
Cell-free DNA (cfDNA)
33%
Clinical Decision-making
33%
Clinical Risk Prediction
33%
Conventional Chemotherapy
33%
End of Treatment
33%
Extranodal NK-T-cell Lymphoma
33%
Heterogeneous Groups
33%
Histology
33%
Lugano Classification
33%
Metabolic Tumor Volume
33%
Minimal Residual Disease
33%
Non-Hodgkin Lymphoma
33%
Peripheral T-cell Lymphoma
100%
Positron Emission Tomography-computed Tomography (PET-CT)
33%
Predictive Biomarker
66%
Prognosis Stratification
100%
Prognostic Implications
33%
Prognosticate
33%
Rare Diseases
33%
Risk Prediction Tool
33%
Risk Stratification
100%
T Cells
33%
Worse Outcome
33%
Medicine and Dentistry
B-Cell Lymphoma
33%
Biological Marker
66%
Brentuximab Vedotin
33%
Cell Free DNA
33%
Clinical Decision Making
33%
Hope
33%
Minimal Residual Disease
33%
Neoplasm
33%
NK T Cell Lymphoma
33%
Non-Hodgkin Lymphoma
33%
Peripheral T-Cell Lymphoma
100%
Positron Emission Tomography-Computed Tomography
33%
Rare Disease
33%
Receptor Gene
33%
Risk Stratification
100%
T Cell
33%
Pharmacology, Toxicology and Pharmaceutical Science
B Cell Lymphoma
33%
Biological Marker
66%
Brentuximab Vedotin
33%
Chemotherapy
33%
Minimal Residual Disease
33%
Neoplasm
33%
NK T Cell Lymphoma
33%
Nonhodgkin Lymphoma
33%
Peripheral T Cell Lymphoma
100%
Rare Disease
33%
Receptor
33%
Immunology and Microbiology
B Cell
25%
Brentuximab Vedotin
25%
Clinical Decision Making
25%
Metabolic Tumor Volume
25%
Natural Killer T Cell
25%
Positron Emission Tomography-Computed Tomography
25%
Receptor Gene
25%
T Cell
100%